We expect these work steps will be completed in the next 30-60 days We operate three businesses; Epigenetics: FOXO Lab’s., remains a pioneer in epigenetic biomarker discovery and commercialization.

FOXO Technologies (FOXO) provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond ...

FOXO Technologies (FOXO) will hold its previously announced Special Meeting of its Shareholders at 10:30 am EST on Friday, January 17, 2025. Following the filing of its Definitive Proxy Statement ...

FOXO Technologies, Inc. ($FOXO) stock jumped about 58% on Thursday after the Minneapolis, Minnesota-based epigenetic biomarkers technology solutions company confirmed ...

In a recent SEC filing, FOXO Technologies Inc. (NYSE American: FOXO), a micro-cap company with a market value of approximately $4 million specializing in commercial physical and biological ...

FOXO Technologies Inc. has provided a shareholder update from its newly appointed CEO, Seamus Lagan, reflecting on recent achievements and outlining future plans. Following a significant change in ...

FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment ...

FOXO Technologies Inc. (NYSE American: FOXO), a micro-cap commercial physical and biological research company with a market capitalization of approximately $4 million, announced today that it ...